M. Baut, Jadwiga Biela-Mazur, Anna Czyżewska-Dudek, R. Kurzawa
{"title":"SARS-CoV-2大流行期间儿童过敏性疾病的管理","authors":"M. Baut, Jadwiga Biela-Mazur, Anna Czyżewska-Dudek, R. Kurzawa","doi":"10.5114/pja.2020.97661","DOIUrl":null,"url":null,"abstract":"The article presents and summarizes the current state of knowledge about the management and treatment of allergic diseases in children during the SARS-CoV-2 pandemic Patients with allergic diseases do not show different symptoms of COVID-19 Children with atopy, like most children, undergo this infection mildly Current recommendations of Polish and international societies recommend continuing the therapy of allergic diseases to minimize the adverse effects of discontinuing treatment Continuing treatment with inhaled and oral glucocorticosteroids, antihistamines and anti-leukotriene drugs is not a risk factor for SARS-CoV-2 infection and should not be stopped Effective treatment of allergic rhinitis may have a positive effect on reducing the transmission of the virus For children with atopic dermatitis it is essential to use barrier preparations to care atopic skin more often to minimize side effects of excessive use of soaps and disinfectant fluids It is not recommended to start immunotherapy with inhaled allergens during a pandemic If there are conditions for epidemiologically safe continuation of specific immunotherapy, the sublingual form is preferred To minimize the risk of transmission of SARS-CoV-2 infection in medical facilities, telemedicine is the preferred method for continuing specialist care","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.97661","citationCount":"1","resultStr":"{\"title\":\"The management of allergic diseases in children during the SARS-CoV-2 pandemic\",\"authors\":\"M. Baut, Jadwiga Biela-Mazur, Anna Czyżewska-Dudek, R. Kurzawa\",\"doi\":\"10.5114/pja.2020.97661\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article presents and summarizes the current state of knowledge about the management and treatment of allergic diseases in children during the SARS-CoV-2 pandemic Patients with allergic diseases do not show different symptoms of COVID-19 Children with atopy, like most children, undergo this infection mildly Current recommendations of Polish and international societies recommend continuing the therapy of allergic diseases to minimize the adverse effects of discontinuing treatment Continuing treatment with inhaled and oral glucocorticosteroids, antihistamines and anti-leukotriene drugs is not a risk factor for SARS-CoV-2 infection and should not be stopped Effective treatment of allergic rhinitis may have a positive effect on reducing the transmission of the virus For children with atopic dermatitis it is essential to use barrier preparations to care atopic skin more often to minimize side effects of excessive use of soaps and disinfectant fluids It is not recommended to start immunotherapy with inhaled allergens during a pandemic If there are conditions for epidemiologically safe continuation of specific immunotherapy, the sublingual form is preferred To minimize the risk of transmission of SARS-CoV-2 infection in medical facilities, telemedicine is the preferred method for continuing specialist care\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.5114/pja.2020.97661\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pja.2020.97661\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2020.97661","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
The management of allergic diseases in children during the SARS-CoV-2 pandemic
The article presents and summarizes the current state of knowledge about the management and treatment of allergic diseases in children during the SARS-CoV-2 pandemic Patients with allergic diseases do not show different symptoms of COVID-19 Children with atopy, like most children, undergo this infection mildly Current recommendations of Polish and international societies recommend continuing the therapy of allergic diseases to minimize the adverse effects of discontinuing treatment Continuing treatment with inhaled and oral glucocorticosteroids, antihistamines and anti-leukotriene drugs is not a risk factor for SARS-CoV-2 infection and should not be stopped Effective treatment of allergic rhinitis may have a positive effect on reducing the transmission of the virus For children with atopic dermatitis it is essential to use barrier preparations to care atopic skin more often to minimize side effects of excessive use of soaps and disinfectant fluids It is not recommended to start immunotherapy with inhaled allergens during a pandemic If there are conditions for epidemiologically safe continuation of specific immunotherapy, the sublingual form is preferred To minimize the risk of transmission of SARS-CoV-2 infection in medical facilities, telemedicine is the preferred method for continuing specialist care
期刊介绍:
Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.